¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"functional profile length"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • length bias
    ±â°£Â÷À̹ÙÀ̾
  • length-height index
    ¸Ó¸®³ôÀ̱æÀÌÁö¼ö
  • quarter wave length matching
    »çºÐÇÒÆÄÁ¶È­
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
  • stride length
    °ÉÀ½°Å¸®
  • short-wave length perimetry
    ´ÜÆÄÀå½Ã¾ßÃøÁ¤(¹ý)
  • wave length
    ÆÄÀå
  • functional amblyopia
    ±â´ÉÀÌ»ó¾à½Ã
  • functional antigen
    ±â´ÉÇ׿ø
  • functional aphasia
    ±â´É¼º¾ð¾î»ó½ÇÁõ, ±â´É¼º½Ç¾îÁõ
  • functional asplenia
    ±â´É¼ºÁö¶ó¾øÀ½(Áõ)
  • functional bleeding
    ±â´ÉÀûÃâÇ÷
  • functional blindness
    ±â´É½Ã°¢»ó½Ç
  • functional capacity
    ±â´É¿ë·®
  • functional cardiovascular disease
    ±â´É¼º½É(Àå)Ç÷°üº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tension length diagram
    Àå·Â±æÀ̵µÇ¥
  • focal length
    ÃÊÁ¡°Å¸®, ÃÊÁ¡±æÀÌ
  • force velocity length relation
    Èû¼Óµµ±æÀ̰ü°è
  • length-height index
    (¢¡altitudinal index) ¸Ó¸®³ôÀ̱æÀÌÁö¼ö
  • length
    ±æÀÌ
  • stride length
    °ÉÀ½°Å¸®
  • wave length
    (¢¡wavelength) ÆÄÀå
  • quarter wave length matching
    »çºÐÇÒÆÄÁ¶È­
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
  • short-wave length perimetry
    ´ÜÆÄÀå½Ã¾ßÃøÁ¤
  • functional amblyopia
    ±â´ÉÀÌ»ó¾à½Ã
  • functional antigen
    ±â´ÉÇ׿ø
  • functional aphasia
    ±â´É¼º¾ð¾î»ó½ÇÁõ
  • functional asplenia
    ±â´ÉÁö¶ó¾øÀ½Áõ
  • functional residual air
    ±â´ÉÀûÀܱâ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Functional hypoglycemia
    ±â´É¼º ÀúÇ÷´çÁõ(¡­î¸úìÓØñø)
  • functional activity
    ±â´É¼º Ȱ¼ºµµ<Ȱµ¿µµ>
  • functional albuminuria
    ±â´É¼º ´Ü¹é´¢.
  • functional amblyopia
    ±â´É¾à½Ã
  • functional antigen
    ±â´É(Àû) Ç׿ø.
  • functional aphasia
    ±â´É¼º ½Ç¾î(Áõ).
  • functional aphasia See aphasia
    ±â´É¼º ½Ç¾î(Áõ)(ѦÒöàõã÷åÞñø)
  • functional aphonia
    ±â´É¼º ½Ç¼º(Áõ).
  • functional aphonia
    ±â´É(Àû) ½Ç¾îÁõ
  • functional aphonia See aphonia
    ±â´É¼º ½Ç¼º(Áõ)(ѦÒöàõã÷á¢ñø)
  • functional apoplexy
    ±â´É¼º Á¹Áß(¡­ðïñé).
  • functional asplenia
    ±â´ÉÀû ¹«ºñÁõ(¡­ÙíÞ¡ñø).
  • functional assessment
    ±â´É¼º »çÀüÆò°¡
  • functional binocular position
    ±â´É¼º¾ç¾È½Ã¾ÈÀ§
  • functional bleeding
    ±â´É¼º(ѦÒöàõ) ÃâÇ÷(õóúì).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • velocity profile
    ¼Óµµ ºÐÆ÷»ó
  • velocity profile
    ¼Óµµ ºÐÆ÷ »óÅ (áÜÓø ÝÂøÖ ßÒ÷¾)
  • velocity profile
    ¼ÓµµºÐÆ÷Çü(áÜöôÝÂøÖúþ).
  • arm length
    »óÁö Àå(ß¾ò¶íþ), »óÁö ±æÀÌ, ÆÈ ±æÀÌ.
  • average length of life
    Æò±Õ¼ö¸í(̰˻ËÛËÎ).
  • average length of stay
    Æò±Õ Àç¿øÀϼö
  • axial length
    ¾È±¸±æÀÌ, ¾ÈÃàÀå
  • body height =body length
    ½ÅÀå(ãóíþ).
  • crown rump length
    µÎÁ¤ µÐºÎ ±æÀÌ
  • crown-heel length
    ¸Ó¸®¸¶·ç¹ß±Á±æÀÌ, Á¤Á¾Àå(ð¢ñ¢íþ).
  • crown-rump length
    Á¤µÐÀå(ð¢Ôëíþ), ¸Ó¸®¸¶·ç¾ûµ¢À̱æÀÌ.
  • crown-rump length
    µÎÁ¤-µÐºÎ (Ôéð¢-ÔëÝ») ±æÀÌ
  • dental length
    Ä¡¿­ÀÇ ±æÀÌ.
  • dominant wave length
    ÁÖÆÄÀå(̡̬Ëö).
  • dominant wave length
    ÁÖÆÄÀå(ñ«÷îíþ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • restriction fragment length polymorphism
    Á¦ÇÑ Á¶°¢±æÀÌ ´ÙÇü¼º(Òýúþàõ)
  • triple-chain length
    »ï(ß²)»ç½½ ±æÀÌ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • profile to X-ray beam
    Á¾´Ü¸é, ¿·¸é
  • section sensitivity profile(SSP)
    ÀýÆí¹Î°¨Ãø¸é
  • slice profile
    ÀýÆíÃø¸éµµ
  • velocity profile
    ¼ÓµµºÐÆ÷»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
FRV full-length retroviral [sequence]; functional residual volume
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
FAI first aid instruction; free androgen index; functional aerobic impairment; functional assessment inv...
FRC Federal Radiation Council; frozen red cells; functional reserve capacity; functional residual capaci...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OHIP Oral Health Impact Profile
POMS Profile Of Mood State
SIP Sickness Impact Profile
SSP Slice sensitivity profile
UPP Urethral pressure profile
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • length of dental arch
    Ä¡¿­±Ã ±æÀÌ
  • length of tooth
    Ä¡¾ÆÀå
    Ä¡¾ÆÀÇ ±æÀÌ.
  • optimal length
    ÃÖÀû ±æÀÌ
  • quarter wave length matching
    4 ºÐÇÒÆÄ Á¶È­
  • span length
    ½ºÆÒ ±æÀÌ, ½ºÆÒÀÇ ±æÀÌ
    2°³ÀÇ ÁöÁö´ë »çÀÌ¿¡ ÀÖ´Â º¸ÀÇ ±æÀÌ.
  • spatial pulse length
    °ø°£ ÆÞ½º ±æÀÌ
  • tension-length curve
    Àå·Â ±æÀÌ °î¼±
  • tension-length diagram curve
    Àå·ÂÀåµµ °î¼±
  • working length
    ±Ù°üÀå
  • functional abnormality
    ±â´ÉÀû ÀÌ»ó
  • functional amblyopia
    ±â´É ¾à½Ã
  • functional aphasia
    ±â´É¼º ½Ç¾î
    È÷½ºÅ׸® ¶Ç´Â ÁßÁõ È÷½ºÅ׸®¼º Àå¾Ö¿¡ ±âÀÎÇÑ ½Ç¾îÁõ.
  • functional articulation
    ±â´É ±³ÇÕ
  • functional brain imaging
    ±â´ÉÀû ³ú ¿µ»ó
  • functional dead space
    ±â´ÉÀû »ç°­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
lipid profile Pattern of lipids in the blood. (A lipid profile usually includes the total cholesterol, high density lipoprotein (hdl) cholesterol, triglycerides, and the calculated low density lipoprotein (ldl) cholesterol.
(12 Dec 1998)
liver profile <investigation> A test that measures the blood serum level of several enzymes produced by the liver. An elevated liver function test is a sign of possible liver damage.
Examples include: prothrombin time, PTT, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, gamma glutamyl transpeptidase, alkaline phosphatase and serum albumin.
(14 Oct 1997)
Lovibond's profile sign The angle made at the meeting of the proximal nail fold and the nail plate when viewed from the radial aspect; normally, less than 180
active length-tension curve The relationship between active isometric tension and preload (rest length) for a contracting muscle.
(05 Mar 2000)
amplified fragment length polymorphism <technique> Invented by KeyGene, a Dutch biotech company based in Wageningen, Holland. The technique is now merchandised under licence agreement by Perkin Elmer.
Selected markers are amplified in a PCR, which makes amplified fragment length polymorphism an easy and fast tool for strain identification in agriculture, botany, microbiology and animal breeding.
Acronym: AFLP
(05 Feb 1998)
arch length The amount of space required for the permanent teeth as measured from the mesial aspect of the first molar on one side to the mesial aspect of the first molar on the opposite side, as measured through the contact points along an imaginary line of the dental arch.
(05 Mar 2000)
arch length deficiency The difference between the available circumference of the dental arch and that required to accommodate the succedaneous teeth in proper alignment.
(05 Mar 2000)
available arch length <dentistry> The amount of space available for the permanent teeth around the dental arch from the first permanent molar on the left to the first permanent molar on the right.
(05 Mar 2000)
back focal length <microscopy> As measured on the principal axis, from the second lens vertex to the back focal point of the lens. It is not the equivalent of the focal length.
(05 Aug 1998)
bellows length <microscopy> The distance from the eye point to the image plane in a photomicrographic apparatus.
(05 Aug 1998)
bond length This is the distance between the nuclei of two atoms which have formed bonds with each other.
(09 Oct 1997)
passive length-tension curve The relationship between passive tension and preload (rest length) for a muscle at rest.
(05 Mar 2000)
required arch length The sum of the mesiodistal widths of the permanent teeth from first permanent molar to first permanent molar.
(05 Mar 2000)
resting length The length at rest from which a muscle develops maximum isometric tension.
(05 Mar 2000)
restriction fragment length polymorphism <molecular biology, technique> A method that allows familial relationships to be established by comparing the characteristic polymorphic patterns that are obtained when certain regions of genomic DNA are amplified (typically by PCR) and cut with certain restriction enzymes.
The variation in the length of DNA fragments produced by a restriction endonuclease that cuts at a polymorphic locus. Such variations are generated by mutations that create or abolish recognition sites for these enzymes.
This is a key tool in DNA fingerprinting, reflecting the existence of different alleles in the individual. Restriction fragment length polymorphism mapping is also used in plant breeding to see if a key trait such as disease resistance is inherited.
In principle, an individual can be identified unambiquously by restriction fragment length polymorphism hence the use of restriction fragment length polymorphism in forensic analysis of blood, hair or semen).
Similarly, if a polymorphism can be identified close to the locus of a genetic defect, it provides a valuable marker for tracing the inheritance of the defect.
Synonym: DNA fingerprinting.
Acronym: RFLP
(12 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • graduated length method
    Á¡Â÷Àû ±æÀÌ º¯°æ¹ý(±â¼úÀÇ Çâ»ó¿¡ µû¶ó ½ºÅ°¸¦ ±ä °ÍÀ¸·Î Á¡Â÷ ¹Ù²Ù¾î °¡´Â ½ºÅ° Áöµµ¹ý)
  • length
    ±æÀÌ;±âÀå;¼¼·Î;±â°£;1¸¶½Å;at full ~ ±æ°Ô;at ~ µåµð¾î;go all ~s;or go to grent(any)~ ¾î¶² ÀÏÀÌ¶óµµ ÇØÄ¡¿ì´Ù
  • whole-length
    ÀüÀå(Àü½Å)ÀÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á